AaviGen is a pre-clinical stage biotechnology company focused on the development of curative gene therapies for genetic and acquired cardiovascular and cardiopulmonary diseases. Its lead program employs heart-specific recombinant Adeno-Associated Viruses (AAV) to bring therapeutic genes with unprecedented safety and precision to the diseased heart via a simple one-time intravenous injection.
The company brings together leading knowledge in clinical cardiology& pneumology, virology&genetic vector engineering as well as gene therapy medicinal product development.
We are looking forward to see your active participation in the network!
You can find here more information about AaviGen.